Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis

Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417-426.

Publication Type:

Journal Article

Authors:

Asselah, T; Kowdley, KV; Zadeikis, N; Wang, S; Hassanein, T; Horsmans, Y; et, al

Source:

Clin Gastroenterol Hepatol, Volume 16, Issue 3, p.417-426 (2018)

Cited On:

Export Citation:
RIS Format
Top